---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018586"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-05-27T20:34:57+00:00"
generated_at: "2026-05-27T20:38:05.970465+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing

## Summary
- Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.
- Safety and tolerability of consolidated first infusion were consistent with established BRIUMVI profile; no Grade 3 or higher infusion reactions occurred.
- Supplemental BLA submission targeted for second half of 2026 based on these results.
- If approved, BRIUMVI would be the first and only IV anti-CD20 therapy initiated with a single infusion.

## SEC filing metadata
- accession: 0001437749-26-018586
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-05-27T20:34:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/0001437749-26-018586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018586
- JSON: https://secwatch.observer/filing/0001437749-26-018586.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.